285 related articles for article (PubMed ID: 32432116)
1. Hi-
Burja B; Mertelj T; Frank-Bertoncelj M
Front Med (Lausanne); 2020; 7():124. PubMed ID: 32432116
[TBL] [Abstract][Full Text] [Related]
2. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Jain NK; Tailang M; Jain HK; Chandrasekaran B; Sahoo BM; Subramanian A; Thangavel N; Aldahish A; Chidambaram K; Alagusundaram M; Kumar S; Selvam P
Front Pharmacol; 2023; 14():1135145. PubMed ID: 37021053
[TBL] [Abstract][Full Text] [Related]
6. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
7. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
8. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
9. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT pathway in pathology of rheumatoid arthritis (Review).
Ciobanu DA; Poenariu IS; Crînguș LI; Vreju FA; Turcu-Stiolica A; Tica AA; Padureanu V; Dumitrascu RM; Banicioiu-Covei S; Dinescu SC; Boldeanu L; Siloși I; Ungureanu AM; Boldeanu MV; Osiac E; Barbulescu AL
Exp Ther Med; 2020 Oct; 20(4):3498-3503. PubMed ID: 32905201
[TBL] [Abstract][Full Text] [Related]
12. Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K; Stoiber D; Sexl V; Witalisz-Siepracka A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073410
[TBL] [Abstract][Full Text] [Related]
13. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
Moura RA; Fonseca JE
Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study.
Retuerto M; Trujillo E; Valero C; Fernandez-Espartero C; Soleto CY; Garcia-Valle A; Aurrecoechea E; Garijo M; Lopez A; Loricera J; Pablos JL
Clin Exp Rheumatol; 2021; 39(3):453-455. PubMed ID: 33938793
[TBL] [Abstract][Full Text] [Related]
15. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
Alexander M; Luo Y; Raimondi G; O'Shea JJ; Gadina M
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056105
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
17. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
18. Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis.
Samarpita S; Ganesan R; Rasool M
Toxicol Appl Pharmacol; 2020 Mar; 391():114917. PubMed ID: 32044269
[TBL] [Abstract][Full Text] [Related]
19. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z
Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790
[TBL] [Abstract][Full Text] [Related]
20. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.
Srivastava S; Rasool M
Life Sci; 2022 Jun; 298():120516. PubMed ID: 35367240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]